Inclusion Criteria:  Aged 18 years of older Written informed consent Scheduled endovascular treatment of femoropopliteal stenotic lesions with a Supera stent Clinically and hemodynamically stable  Exclusion Criteria:  Occluded superficial femoral artery or popliteal artery Origin stenosis of the superficial femoral artery (within 5 cm of the bifurcation) Superficial femoral artery and/or popliteal artery diameter larger than 6.5 mm Severely impaired renal function (eGFR < 30 ml/min), end stage renal disease Cardiac insufficiency (NYHA 3-4) Hypersensitivity to iodinated contrast media BMI > 25 and contralateral approach not possible Minimal lumen diameter of target lesion < 1.5 mm Presence of a hemodynamically significant inflow stenosis in the aorto-iliac tract or the common femoral artery Participating in another trial with an investigational drug or medical device concerning the femoropopliteal tract interfering with the current study Life expectancy of less than 24 months Women of child-bearing age not on active birth control Legally incapable